Concepedia

Mecide Gharibo

MG

Statistics

Publications

20

Citations

1.4K

H-Index

14

Active since

2007

Affiliations

Rutgers, The State University of New Jersey(Current)

Rutgers Cancer Institute

Bristol-Myers Squibb (United States)

University of California, San Francisco

Dana-Farber Cancer Institute

Mecide Gharibo is an author at Rutgers, The State University of New Jersey specializing in medicine, oncology, and hematologic malignancy therapy.

Publications per year

2007–2023

20

Publications

20

Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial

Sagar Lonial, Brendan M. Weiss, Saad Z. Usmani et al. · The Lancet · 2016 · 850 citations

, , +14

<i>Lactobacillus rhamnosus GG</i> probiotic enteric regimen does not appreciably alter the gut microbiome or provide protection against GVHD after allogeneic hematopoietic stem cell transplantation

Elan Gorshein, Catherine Wei, Susan Ambrosy et al. · Clinical Transplantation · 2017 · 74 citations

, , +17

Avadomide monotherapy in relapsed/refractory DLBCL: safety, efficacy, and a predictive gene classifier

Cecilia Carpio, Réda Bouabdallah, Loïc Ysebaert et al. · Blood · 2020 · 73 citations · Full text

, , +8

A Phase I Study to Assess the Safety and Pharmacokinetics of Single-agent Lorvotuzumab Mertansine (IMGN901) in Patients with Relapsed and/or Refractory CD–56-positive Multiple Myeloma

Sikander Ailawadhi, Kevin R. Kelly, Robert Vescio et al. · Clinical Lymphoma Myeloma & Leukemia · 2018 · 64 citations · Full text

, , +12

A phase I/II study of KW-2478, an Hsp90 inhibitor, in combination with bortezomib in patients with relapsed/refractory multiple myeloma

Jamie Cavenagh, Heather Oakervee, P Baetiong-Caguioa et al. · British Journal of Cancer · 2017 · 54 citations · Full text

, , +14

1–5 of 20